ANSTO to manufacture skin cancer treatment

Nuclear science and technology organisation ANSTO has been licensed as the Australian manufacturing partner of a new non-invasive treatment for non-melanoma skin cancer (NMSC).

Radioisotope developer OncoBeta and ANSTO will establish local manufacturing of the company’s epidermal radioisotope therapy, Rhenium-SCT (Skin Cancer Therapy) for the treatment of non-melanoma skin cancer.

ANSTO operates the OPAL nuclear reactor in Sydney, which produces radioisotopes for medicine and is involved in silicon production and materials research.

OncoBeta is increasing activities in Australia alongside the International Registry and the EPIC-Skin study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer) – researching the efficacy, safety, quality of life, treatment comfort and cosmetic outcomes.

Rhenium-SCT has already been used to successfully treat 1,900 NMSC lesions from patients around the world.

The radioisotope Rhenium-188 is applied only to the area requiring treatment, sparing healthy tissue.

ANSTO CEO Shaun Jenkinson said: “We’re very proud to team up with OncoBeta to establish local manufacturing of Rhenium-SCT on our campus and to see Australian patients gain access to this innovative new therapy.

“Our core mission is to improve the health of Australians and to support industry – this partnership enables us to do both.”

ANSTO’s General Manager of Business Development and Commercialisation Rosanne Robinson ANSTO’s Lucas Heights Campus in Sydney was focused on attracting entrepreneurs and innovative companies who want to leverage the opportunity to access its expertise in the nuclear industry.

OncoBeta recently announced the commencement of the EPIC-Skin study with the world’s very first patients being treated at Gold Coast. ANSTO will be manufacturing and supplying the Rhenium-188 to all study centres in Australia.

Picture: ANSTO/OPAL reactor

Subscribe to our free @AuManufacturing newsletter here.

Share this Story

Stay Informed

Go to Top